Across TCGA pan-cancer cohorts, CD300E Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD300E data layer compared with 24 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CD300E Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CD300E expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, TGCT, and SKCM are the cancer types where CD300E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.439	.019	24	view →
TGCT	DFS	Median	II,III,IV	0.088	0.917	.010	6	view →
SKCM	OS	Median	All	0.977	0.866	.040	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CD300E tumor-vs-normal RNA expression · all CD300E data types